The most common reason Americans use medical cannabis — with strong meta-analytic evidence.
Chronic pain — defined as pain persisting beyond 3 months — affects more Americans than diabetes, heart disease, and cancer combined. It encompasses neuropathic pain, musculoskeletal pain, inflammatory pain, and cancer pain. Medical cannabis is the most common reason patients enroll in state medical programs, and the evidence base is among the strongest in cannabis medicine.
50 million adults
Americans Affected
20.4% of U.S. adults (50+ million)
Prevalence
4
Key Studies
4
Cannabinoids Reviewed
Cannabis activates CB1 and CB2 receptors throughout the pain-processing pathway — from peripheral sensory neurons to the spinal cord dorsal horn to the brain's pain-modulation centers. A 2017 meta-analysis of RCTs found cannabis significantly reduced chronic pain (SMD = -0.61). A 2026 cohort study of 500,000 patients found medical cannabis enrollment associated with 34% reduction in opioid prescriptions.
CB1 receptors are densely expressed in pain-processing regions: the periaqueductal gray (PAG), rostral ventromedial medulla (RVM), spinal cord dorsal horn, and peripheral sensory neurons. THC activation of CB1 in these regions produces analgesia via mechanisms that partially overlap with opioid pathways.
CB2 receptors on immune cells (macrophages, microglia) regulate neuroinflammation — a key driver of neuropathic and inflammatory pain. CBD and CBG activate CB2 receptors, reducing pro-inflammatory cytokine release and central sensitization.
CBD desensitizes TRPV1 (the capsaicin receptor), a key pain transducer in peripheral sensory neurons. TRPV1 desensitization reduces the transmission of pain signals from the periphery to the spinal cord.
Cannabinoids and opioids have synergistic analgesic interactions. Cannabis can enhance opioid analgesia, allowing dose reduction (opioid-sparing effect). The 2026 JAMA Internal Medicine cohort study found 34% opioid MME reduction in medical cannabis enrollees.
THC has the strongest analgesic evidence, particularly for neuropathic pain. Dose-dependent psychoactivity requires careful titration. 1:1 THC:CBD (nabiximols) is the best-evidenced formulation.
CBD reduces neuroinflammation and central sensitization. Less effective than THC for acute nociceptive pain but valuable for inflammatory and neuropathic components.
CBG's potent anti-inflammatory activity (comparable to mesalazine in IBD models) may benefit inflammatory pain conditions.
CBC activates TRPA1 channels and has demonstrated analgesic activity in preclinical models. Contributes to full-spectrum entourage effects.
Medical Cannabis for Chronic Pain: Meta-Analysis
Cannabis significantly reduced chronic pain vs. placebo (SMD = -0.61) across neuropathic, cancer, and musculoskeletal pain in meta-analysis of RCTs.
Medical Cannabis and Opioid Use: 500,000-Patient Cohort
Medical cannabis enrollment associated with 34% reduction in opioid MME; 38% reduction in chronic non-cancer pain patients.
Smoked Cannabis for Neuropathic Pain
Cannabis 9.4% THC reduced neuropathic pain intensity and improved sleep quality vs. placebo in crossover RCT.
Nabiximols for Cancer Pain
Low-dose nabiximols (THC:CBD 1:1) significantly improved pain in opioid-treated cancer patients with inadequate control.
Dosing information is for educational purposes only. Always start with the lowest effective dose and consult a healthcare provider before use.
Start Dose
1–2 sprays (2.7mg THC / 2.5mg CBD each)
Target Dose
8–12 sprays/day
Timing
Titrate over 2 weeks; spread doses throughout day
Best-evidenced formulation for neuropathic and cancer pain. Approved in 30+ countries as Sativex.
Start Dose
5mg THC + 5mg CBD
Target Dose
15–30mg THC + 15–30mg CBD
Timing
With food; 2–3x daily
Slower onset but longer duration (4–8 hours). Preferred for chronic baseline pain management.
Start Dose
1–2 puffs
Target Dose
Titrate to effect
Timing
For breakthrough pain episodes
Fastest onset (minutes). Use for acute pain flares. Limit frequency to reduce tolerance development.